Company research

OKYO Pharma Ltd

CIK 1849296Updated Sep 26, 2026

SecurityOKYO · NASDAQ · equity

OKYO price & chart

Provider market data

Loading TradingView…

NASDAQ:OKYO on TradingView ↗

TradingView · Data may be delayed

In the news

OKYO Pharma Announces Public Offering of Ordinary Shares ↗

GlobeNewswire · 2026-02-12

Seeking Alpha

OKYO Pharma chairman increases stake with share purchase ↗

Seeking Alpha · 2026-07-21

Most and least shorted healthcare stocks with up to $2B market cap in March ↗

Seeking Alpha · 2026-04-03

Recent filings

6-K filing
6-K · 2026-09-09 · 0001493152-26-041864
6-K filing
6-K · 2026-09-08 · 0001493152-26-041686
20-F/A filing
20-F/A · 2026-08-07 · 0001493152-26-036599
4/A filing
4/A · 2026-08-07 · 0001493152-26-036584
4/A filing
4/A · 2026-08-07 · 0001493152-26-036583

Show 5 more recent filings

4/A filing
4/A · 2026-08-07 · 0001493152-26-036579
4/A filing
4/A · 2026-08-07 · 0001493152-26-036582
6-K filing
6-K · 2026-07-28 · 0001493152-26-034927
6-K filing
6-K · 2026-07-27 · 0001493152-26-034686
4 filing
4 · 2026-07-23 · 0001493152-26-034408

Financials

FY 2025 · USD

Revenue— · FY 2025

Net income— · FY 2025

Assets—USD · FY 2025

Cash— · FY 2025

Operating income— · FY 2025

Diluted EPS-0.2USD per share · FY 2025

Source

20-F · 2025-07-18 · 0001641172-25-020240

2024-04-01 to 2025-03-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements

Line item	FY 2025	FY 2024	FY 2023	FY 2022
Cash flows from operating activities:
Profit or LossUSD	-4,706,292 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	-16,825,461 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	-13,271,685 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	-5,431,045 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
Additional Financial Items
AdjustmentsForCurrentTaxOfPriorPeriodUSD	-3,263,830 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	-32,864 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	-12,202 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	-277,239 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
AdjustmentsForIncomeTaxExpenseUSD	-3,263,779 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	22,416 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	—	—
AdjustmentsForSharebasedPaymentsUSD	734,989 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	1,121,273 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	1,286,128 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	1,737,876 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD	-96,978 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	55,183 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	51,192 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	-9,230 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
ProceedsFromIssuingSharesUSD	—	—	7,323,354 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	—

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements

Line item	FY 2025	FY 2024	FY 2023	FY 2022
Additional Financial Items
ApplicableTaxRatenumber	0.19 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	0.19 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	0.19 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	0.19 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31
BasicEarningsLossPerShareUSD per share	-0.2 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	-0.57 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	-0.61 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	—
CurrentTaxExpenseIncomeUSD	51 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	55,280 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	—	-509,282 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
DepreciationAndAmortisationExpenseUSD	2,563 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	3,866 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	3,797 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	2,423 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
DilutedEarningsLossPerShareUSD per share	-0.2 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	-0.57 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	-0.61 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	—
EmployeeBenefitsExpenseUSD	2,112,210 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	2,662,909 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	1,918,330 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	1,129,279 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
FinanceCostsUSD	878,174 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	1,053,313 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	96,687 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	—
FinanceIncomeUSD	5,473 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	—	—	—
IncomeTaxExpenseContinuingOperationsUSD	3,263,779 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	-22,416 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	12,202 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	786,521 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
PostemploymentBenefitExpenseDefinedContributionPlansUSD	6,277 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	5,598 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	6,510 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	2,622 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
ProfessionalFeesExpenseUSD	1,005,883 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	1,377,774 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	1,432,926 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	1,143,300 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
ProfitLossBeforeTaxUSD	-7,970,071 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	-16,803,045 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	-13,283,887 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	-6,217,566 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
ResearchAndDevelopmentExpenseUSD	2,254,244 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	8,243,571 Source 20-F · 2024-08-13 · 0001493152-24-031640 2023-04-01 to 2024-03-31	6,337,698 Source 20-F · 2023-08-15 · 0001493152-23-028739 2022-04-01 to 2023-03-31	1,301,178 Source 20-F · 2022-08-15 · 0001493152-22-022836 2021-04-01 to 2022-03-31
RevenueFromInterestUSD	5,473 Source 20-F · 2025-07-18 · 0001641172-25-020240 2024-04-01 to 2025-03-31	—	—	—

Lines labelled “Derived” are calculated from reported figures.